A new study provides insight into aging and agerelated diseases by linking telomere dysfunction to a decline in mitochondrial number and function.
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Now, a new study by Ronald DePinho and colleagues suggests that both sides of what might be called this age-old debate might have been right all along. This new study demonstrates that telomeres, through p53, act to regulate overall metabolic function. 2 In making such a connection, the mitochondria and the nucleus appeared to have gotten a lot closer and the basis for why we age has became a lot clearer.
The model used to connect telomeres with mitochondrial function involved a mouse with impaired telomere maintenance caused by a targeted deletion of the enzyme telomerase. These Tert Ϫ/Ϫ animals have been shown previously to develop severely short telomeres when backcrossed for four or more generations (known as G4 or generation 4 mice). Interestingly, the G4 Tert Ϫ/Ϫ animals developed pathologies not only in highly proliferative tissues, as might be expected, but also in predominantly postmitotic organs, such as the heart. To understand how nonproliferating tissues, such as the heart, might be affected by the absence of telomerase, DePinho and colleagues analyzed the transcriptome of wildtype and G4 mice. Strikingly, pathway analysis revealed that the absence of telomerase led to significant alterations in those genes regulating oxidative phosphorylation, mitochondrial function, antioxidant defense and metabolism. The authors then realized that a family of transcriptional regulators, peroxisome proliferator-activated receptor gamma coactivator 1 alpha and beta (PGC-1␣ and PGC-1␤) had been implicated as an important regulator of all these processes. This suggested that telomere shortening might somehow repress the expression of PGC-1␣ and PGC-1␤. The author subsequently confirmed this hypothesis and then proceeded to show that telomere dysfunction results in reduced mitochondrial number and function in the heart, as well as other tissues. Interestingly, reinstitution of telomerase could, at least partially, correct the mitochondrial dysfunction.
The authors next sought to understand how telomere shortening represses the expression of the PGC-1 family of coactivators. Here, they took advantage of previous observations that in their mouse model, p53 was activated as a consequence of telomere attrition. 3 Furthermore, past studies had shown that animal models exhibiting constitutively activated p53 are often characterized by a phenotype consistent with accelerated aging. 4, 5 Using both genetic and biochemical approaches, the authors demonstrated that telomere dysfunction activated p53, and once activated, p53 was an important and physiologic repressor of PGC-1␣ and PGC-1␤ expression. This led to a model wherein telomere shortening and, by extension, aging leads to the activation of a p53-dependent pathway that culminates in altered mitochondrial function (see Figure) .
What are the implications of these results for human aging and for the treatment of age-related pathologies? Interestingly, recent analysis has demonstrated that in humans, conditions associated with a genetic impairment of telomere maintenance results in a constellation of symptoms, including inherited bone marrow failure, pulmonary fibrosis, and hepatic cirrhosis. 6 Although these families do not appear to spontaneously develop cardiovascular disease, there are a number of other studies linking shortened telomeres to higher susceptibility for cardiovascular disease. 7 It will, therefore, be of interest to see whether in any of the above situations, shortening of telomeres results in measurable alterations in mitochondrial number or function. Follow-up studies may also be able to tease out the relative importance of p53 as a repressor of PGC-1␣ and PGC-1␤ expression vs. its other well-described role in mediating growth arrest, apoptosis, or senescence. It is conceivable that different organs and tissues will differ considerably in the relative importance of the various p53-regulated pathways. In essence, aging may not be a uniform process in the body, and different tissues may age at different rates and through different mechanisms. Therapeutically, one implication of this new study is that augmenting PGC-1␣ and PGC-1␤ expression might be able to reverse some of the age-dependent decline in tissue or organ function. Although this possibility is intriguing, it is important to note that too much PGC-1␣ and PGC-1␤ expression can have adverse effects, as well. 8 Further analysis will hopefully address these and related questions. At least for now, the description of a molecular connection between DNA maintenance and mitochondrial function represents an important first step. Furthermore, these results strengthen the intriguing notion that the molecular basis for why we develop conditions, such as heart failure or atherosclerosis, may be buried within the secrets of how and why we age.
